Funds Holding Derma Sciences, Inc.

 
Stock Quotes for Derma Sciences, Inc. top ^
  • Industry: Medical Instruments & Supplies
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for dsci investment picks

 
News Articles for Derma Sciences, Inc. top ^
2013/2/6
Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announces that enrollment of patients has commenced in the first of two Phase 3 clinical trials with the Company’s investigational topical drug candidate DSC127.
Sign-up for Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers investment picks
2013/3/15
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will file its Form 10-K for 2012 with the U.S. Securities and Exchange Commission (SEC) after market close on Thursday, March 28, will report 2012 fourth quarter and full year financial results via a news release to be issued premarket Monday, April 1 and will hold an investment community conference call to discuss the financial results and answer questions at 11:00 a.m. Eastern time April 1.
Sign-up for Derma Sciences Announces Timing for Fourth Quarter Conference Call and 2012 Form 10-K Filing investment picks
2013/3/14
Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will be presenting at the 25 th Annual ROTH Conference on Tuesday, March 19 at 12:00 p.m. Pacific Time.
Sign-up for Derma Sciences to Present at the 25th Annual ROTH Conference investment picks
2013/4/1
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that it has signed a long-term exclusive global rights agreement with New Cast Industries Co.
Sign-up for Derma Sciences Expands TCC-EZ® Market Reach with Long-Term Exclusive Global Rights Agreement investment picks
2013/4/1
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the fourth quarter and year ended December 31, 2012.
Sign-up for Derma Sciences Reports 2012 Fourth Quarter and Full Year Financial Results investment picks
2013/4/19
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Derma Sciences, Inc. (“Derma” or the “Company”) (NasdaqCM: DSCI) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment to the Company’s 2012 Incentive Plan.
Sign-up for Faruqi & Faruqi, LLP Launches an Investigation against Derma Sciences, Inc. (DSCI) for Potential Breaches of Fiduciary Duties by Its Board of Directors investment picks
2013/4/22
Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.
Sign-up for Derma Sciences to Present at the 12th Annual Needham Healthcare Conference investment picks
2013/4/22
NEW YORK, April 22, 2013 (GLOBE NEWSWIRE) -- via PRWEB - Derma Sciences, Inc. is pleased to announce that Ed Quilty, President & CEO of Derma Sciences, Inc. (Nasdaq:DSCI) will be presenting at the Taglich Brothers 10th Annual Small Cap Equity Conference May 7, 2013.
Sign-up for Derma Sciences to Present at Taglich Brothers 10th Annual Small Cap Equity Conference investment picks
2013/4/25
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.
Sign-up for Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot Ulcers investment picks
2013/5/7
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announced today that it will hold a conference call on May 16, 2013 to discuss the financial results for the first quarter of 2013.
Sign-up for Derma Sciences to Hold First Quarter Financial Results Conference Call on May 16th investment picks
2013/5/14
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announces that it has engaged Plexus Ventures, a leading strategic advisor to the pharmaceutical, biotechnology and drug delivery industries worldwide, to explore options for DSC127 outside the U.S. The process is expected to take nine to 15 months and to culminate with one or more agreements covering specific geographies or countries in Europe, Asia and emerging markets.
Sign-up for Derma Sciences Engages Plexus Ventures to Explore Strategic Options for DSC127 Outside the U.S. investment picks
2013/5/16
Derma Sciences, Inc. (Nasdaq: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March 31, 2013.
Sign-up for Derma Sciences Reports First Quarter 2013 Financial Results investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Funds Holding Derma Sciences, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Depomed, Inc.  |  Next: Funds Holding Deutsche Bank AG